期刊
SEMINARS IN IMMUNOLOGY
卷 22, 期 3, 页码 105-112出版社
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.smim.2010.02.001
关键词
Cancer; Vaccine(s); Immunotherapy; Immunosurveillance
类别
资金
- Alliance for Cancer Gene Therapy, Inc. [5P01CA109094]
- NATIONAL CANCER INSTITUTE [P01CA109094] Funding Source: NIH RePORTER
Despite enormous effort, promising pre-clinical data in animal studies and over 900 clinical trials in the United States, no cancer vaccine has ever been approved for clinical use. Over the past decade a great deal of progress has been in both laboratory and clinical studies defining the interactions between developing tumors and the immune system. The results of these studies provide a rationale that may help explain the failure of recent therapeutic cancer vaccines in terms of vaccine principles, in selecting which tumors are the most appropriate to target and instruct the design and implementation of state-of-the-art cancer vaccines. (C) 2010 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据